GKOS's Quality Score rose 2 points on Tue, Nov 3, to 16.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 34% on Oct 29, and still 32% over its Oct 28 close.
| Sales | Up 22% a year for 3 years vs 5% for its peers |
| Latest filing | 8-K, Oct 28 |
Tue Nov 10: Stifel Healthcare Conference 2026Investor conference · date confirmed.
3 more dates ahead: conferences, for Pro members.
After its last 4 reports it closed +18.6% on average, higher 4 of 4 times.
Excellentfor quality, not price, 6 of 14 chart checks firingWhat the Quality Score means
Well above its recent run. GKOS scores 16 today, against a median of 9.5 over its last 20 recorded sessions.
GKOS is #4 of 85 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 4 |
Share count against a year before: GKOS +2.8%, HAE -5.7%.
Expected to report Tue Feb 16, after the close (in 105 days). Expected.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $211.0M, 58% more than a year ago; a profit of $0.03 a share, from a loss of $0.28.
“Our third quarter record results reflect a sustained growth acceleration in our business with the strong performance driven by growing iDose® TR adoption and utilization, along with our broader Interventional Glaucoma, or IG, initiatives globally, as well as growing contributions of Epioxa®.”
GKOS's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| Net sales | $775M to $785M |
Sales grew 18% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 5.1% a year over 5 years.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Oct 28, 2026 | +16.3% | +33.6% | open |
| Jul 29, 2026 | +11.5% | +4.2% | +5.7% |
| Apr 29, 2026 | +21.0% | +22.8% | +15.7% |
Sales grew in five of the last seven years, to $507M in 2025. It made a profit in one of the eight years.
4 insiders sold $15.2M across 9 filings in the last 6 months. No open-market buys on record. The newest:
3 trades disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: GKOS is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
GKOS scores 16 today, which Breakaway calls Excellent. It is #4 of 85 in Medical Devices by Quality Score, with 6 of 14 chart checks firing. Up 34% on Oct 29, and still 32% over its Oct 28 close. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
GKOS scores 16 today, which Breakaway calls Excellent (15 to 19). That is #4 of 85 in Medical Devices by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind GKOS's 16.
4 insiders sold $15.2M across 9 filings in the last 6 months. No open-market buys on record. The newest is Tomas Navratil, Chief Development Officer, who sold $1.4M on Aug 28. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.